Table 2 Clinical trials involving bispecific antibodies in AML

From: Acute myeloid leukemia targets for bispecific antibodies

Name

Format

Phase

Endpoint

Clinical trial number

Sponsor

Study population

Status

JNJ-63709178

CD123 × CD3 DuoBody

1

Safety and efficacy

NCT02715011

Janssen Research & Development, LLC

Relapsed/refractory AML

Suspended

AMG 330

CD33 × CD3 Tandem scFv (BiTE)

1

Safety

NCT02520427

Amgen

Relapsed/refractory AML

Suspended

MGD006

CD123xCD3 DART

1

Safety

NCT02152956

MacroGenics

Relapsed/refractory AML, MDS

Recruiting

  1. Abbreviations: AML, acute myeloid leukemia; BiTE, bispecific T-cell engager; DART, dual-affinity re-targeting; MDS, myelodysplastic syndrome.
  2. DuoBody (Genmab, Copenhagen, Denmark) is the commercialized name of the controlled Fab-arm exchange (cFAE) platform to generate IgG1 monovalent bispecific antibodies.145
Back to article page